Investor Overview

Webcast ImageWebcast
AtriCure, Inc. at Morgan Stanley Global Healthcare Conference  (Live)
09/12/17 at 5:15 p.m. ET
Webcast ImageWebcast
AtriCure, Inc. at Canaccord Genuity 37th Annual Growth Conference (Replay)
08/10/17 at 1:00 p.m. ET
Webcast ImageWebcast
Q2 2017 AtriCure, Inc. Earnings Conference Call (Replay)
07/27/17 at 4:30 p.m. ET

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$22.37 + 0.190.86%182,760
Previous CloseToday's OpenIntraday HighIntraday Low
$22.18$21.99$22.48$21.99
Exchange: NASDAQ (US Dollar)
08/18/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
08/18/17
Download Documentation Investor Presentation
04/18/17
Download Documentation 2016 Annual Report

All Recent News

DateTitle 
08/18/17AtriCure to Present at the Morgan Stanley Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Aug. 18, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York on Tuesday, September 12, 2017. Management is scheduled to present at 5:15 p.m. Eastern Time. A live audio webcast of the presenta... 
Printer Friendly Version
07/27/17AtriCure Reports Second Quarter 2017 Financial Results
Worldwide revenue of $45.2 million – an increase of 14.0% year over year U.S. revenue of $35.5 million – an increase of 15.1% year over year International revenue of $9.7 million – an increase of 10.2% year over year MASON, Ohio--(BUSINESS WIRE)--Jul. 27, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial a... 
Printer Friendly Version
07/20/17AtriCure to Present at the Canaccord Genuity 37th Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 20, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 37th Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 10, 2017. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of t... 
Printer Friendly Version
07/18/17AtriCure Announces Hiring of Chief Technology Officer
MASON, Ohio--(BUSINESS WIRE)--Jul. 18, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Salvatore (Sam) Privitera as its Chief Technology Officer. Mr. Privitera will have responsibility for Research and Development activities, as well as Operations, including manufacturing, supply chain, and quality systems. Mos... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
08/18/17AtriCure to Present at the Morgan Stanley Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Aug. 18, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York on Tuesday, September 12, 2017. Management is scheduled to present at 5:15 p.m. Eastern Time. A live audio webcast of the presenta... 
Printer Friendly Version
07/27/17AtriCure Reports Second Quarter 2017 Financial Results
Worldwide revenue of $45.2 million – an increase of 14.0% year over year U.S. revenue of $35.5 million – an increase of 15.1% year over year International revenue of $9.7 million – an increase of 10.2% year over year MASON, Ohio--(BUSINESS WIRE)--Jul. 27, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial a... 
Printer Friendly Version
07/20/17AtriCure to Present at the Canaccord Genuity 37th Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 20, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 37th Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 10, 2017. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of t... 
Printer Friendly Version
07/18/17AtriCure Announces Hiring of Chief Technology Officer
MASON, Ohio--(BUSINESS WIRE)--Jul. 18, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Salvatore (Sam) Privitera as its Chief Technology Officer. Mr. Privitera will have responsibility for Research and Development activities, as well as Operations, including manufacturing, supply chain, and quality systems. Mos... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
04/25/17AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, which makes it the most widely used of all d... 
Printer Friendly Version
03/14/17AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology... 
Printer Friendly Version
11/01/16AtriCure Announces Approval for the cryoICE™ Platform in Japan
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation ... 
Printer Friendly Version
06/29/16AtriCure Receives CE Mark for the AtriClip® PRO2 Device
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left ... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
09/12/17 
5:15 p.m. ET
AtriCure, Inc. at Morgan Stanley Global Healthcare Conference
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.